Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2313952 | 0.90 | GCGR (0.40) | GCGRMGLLMEN1TP53CYP3A4 | |
| SCHEMBL2316800 | 0.90 | GCGR (0.40) | GCGRMGLLMEN1TP53CYP3A4 | |
| SCHEMBL2337738 | 0.90 | GCGR (0.40) | GCGRMGLLMEN1TP53CYP3A4 | |
| SCHEMBL585686 | 0.89 | PTGS2 (0.35) | CYP3A4 | |
| SCHEMBL585042 | 0.87 | TLR8 (0.36) | GCGR | |
| SCHEMBL7181079 | 0.85 | MEN1 (0.34) | MEN1TP53CYP3A4ALOX5MAPT | |
| SCHEMBL2202844 | 0.84 | TSHR (0.37) | TSHR | |
| SCHEMBL7180826 | 0.84 | MEN1 (0.34) | MEN1TP53CYP3A4ALOX5MAPT | |
| SCHEMBL584790 | 0.83 | HSD17B1 (0.37) | CYP3A4 | |
| SCHEMBL2360345 | 0.82 | CYP1A2 (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-1897883-A2 | Cationic porphyrin derivatives as antibacterial agents | Destiny Pharma Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | GCGR 4314/4885MGLL 4326/4885MEN1 166/4885 |
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | GCGR 3494/4885MGLL 4657/4885MEN1 469/4885 |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | GCGR 3672/4885MGLL 4528/4885MEN1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.